What To Expect From UL Solutions’s (ULS) Q2 Earnings

UL Solutions (NYSE: ULS) reports Q2 earnings Tuesday before market open. The company’s prior quarter revenue was $758M, up 7.5% YoY, beating revenue and EPS estimates. For Q2, analysts expect revenue up 4.9% YoY. ULS has an average analyst price target of $108.95 vs $91.66.

Original reporting
Published Aug 3, 2026, 3:04 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 3, 2026, 5:51 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
What To Expect From UL Solutions’s (ULS) Q2 Earnings — source image
Decision brief

The 30-second read

$ULSNeutralMed
01

Why it matters

Traders can use the provided consensus growth rate and the company’s prior beat history to position for earnings volatility, but the text does not add new fundamental disclosures beyond the scheduled report timing.

02

Market read

This is an earnings preview with consensus revenue growth and sentiment context, useful for near-term positioning into the pre-market release.

03

What to watch

The preview lacks margin, backlog, guidance, and order-flow details, which are typically the key drivers for certification and testing services earnings reactions.

Relevance 4/10Novelty 4/10Timing: ahead of Tuesday pre-market Q2 earnings

Background

UL Solutions is a safety certification company; the article frames expectations for its upcoming Q2 earnings and compares peer results in the professional services space.

Company-level read

Ticker impact

$ULSNeutralMedium confidence
Context

UL Solutions is set to report Q2 results Tuesday pre-market, with revenue growth expectations of 4.9% YoY and prior-quarter beats.

Expected impact

Near-term volatility likely around revenue/EPS versus expectations; direction depends on whether the 4.9% YoY growth and EPS beat trend holds.

Evidence & confidence

The article provides consensus expectations and notes a history of exceeding estimates, but it does not disclose any new guidance, filings, or surprises beyond the upcoming earnings timing.

Market effects

Professional services sentiment is described as positive, but the piece is primarily a single-name earnings setup rather than a sector catalyst.

No specific regional impact is discussed.

No global macro or cross-border catalyst is discussed.

Counterpoint

A modest slowdown in expected revenue growth (4.9% vs 6.3% prior year) could mean the stock’s run-up is vulnerable if the beat is smaller than hoped.

Key entities

  • UL Solutions

    Subject of the article, scheduled to report Q2 results Tuesday before market open.

  • Booz Allen Hamilton

    Peer cited as having reported Q2 revenue down 4.2% YoY and missing by 0.5%, with an 8.8% post-results move.

  • Ryan Specialty

    Peer cited as having reported Q2 revenue up 7.2% YoY and topping estimates by 5.3%, with stock price unchanged.

Related articles

$ULSHigh

UL Solutions Inc. (ULS): Results of Operations and Financial Condition

UL Solutions Inc. (ULS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991q22026ulsolution.htm EX-99.1 Document Exhibit 99.1 UL Solutions Inc. Reports Strong Second Quarter 2026 Results Second Quarter 2026 1 • Strong revenue growth of 5.2% to $816 million, including 6.6% organic revenue growth • Net income of $254 million increased

$WFCFMedAI 8/10

WFCF Q2 2026 Earnings Call Transcript

Where Food Comes From, Inc. (WFCF) reported Q2 2026 revenue of $6.6M, up slightly year over year, with verification and certification revenue of $5.4M. Gross profit rose to $2.7M and operating income to $665K. Net income was $413K, or $0.08/share, down from $0.11/share, partly due to a $240K negative digital asset fair value swing. The company also discussed M&A plans and a shelf registration filing.

$INMBMed

INmune Bio (INMB) Q2 2026 Earnings Call Transcript

INmune Bio (INMB) reported Q2 2026 results on an earnings call, with net loss attributable to common shareholders of $1.3 million versus a prior-year $16.5 million impairment charge. Cash and cash equivalents were $18.4 million as of June 30, 2026, expected to fund operations into Q2 2027. The company discussed Ebstracel MHRA alignment and planned late-2026 conditional authorization, plus XPro Alzheimer MRI biomarker effects.